Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kindstar Globalgene Technology, Inc. ( (HK:9960) ) has shared an update.
Kindstar Globalgene Technology, Inc. has issued a profit warning, anticipating a net loss of RMB30 million to RMB35 million for the first half of 2025, compared to a net profit of RMB10.5 million in the same period of 2024. The losses are attributed to a decrease in revenue, losses from fair value changes on funds, expected credit losses related to COVID-19, and expenses from recent acquisitions. Despite these challenges, the company’s core business remains stable.
The most recent analyst rating on (HK:9960) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Kindstar Globalgene Technology, Inc. stock, see the HK:9960 Stock Forecast page.
More about Kindstar Globalgene Technology, Inc.
Kindstar Globalgene Technology, Inc. operates in the biotechnology industry, focusing on providing specialized diagnostic services and solutions. The company is involved in the acquisition of other biotech firms to expand its market presence.
Average Trading Volume: 965,937
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.77B
See more data about 9960 stock on TipRanks’ Stock Analysis page.